Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
虎杖痛风颗粒 (HZKL) is a traditional Chinese medicine (TCM) formulation primarily used for the treatment of gout and hyperuricemia. The main ingredient is Polygonum cuspidatum (Japanese knotweed), which contains active compounds such as resveratrol and emodin. These components are believed to exert anti-inflammatory, uric acid-lowering, and analgesic effects. The mechanism of action involves inhibition of xanthine oxidase activity to reduce uric acid production, promotion of uric acid excretion via the kidneys, and suppression of inflammatory mediators associated with acute gout attacks. HZKL is typically prescribed in China as an oral granule preparation for patients with acute or chronic gouty arthritis or elevated serum uric acid levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 虎杖痛风颗粒.